Document is current
Any future updates will be listed below
-
Authors
Galor, Anat
Abbott, Kaleb
Henderson, Bonnie
Pflugfelder, Steve
White, Darrell
Gupta, Preeya
Periman, Laura
Stefater, James A.
Stryjewski, Tomasz P.
Ifantides, Cristos https://orcid.org/0000-0003-2289-6656
Karpecki, Paul
- License Information
-
More Information
Article History
Received: 27 May 2025
Accepted: 12 August 2025
First Online: 5 September 2025
Declarations
:
: Anat Galor—Alcon Bausch + Lomb, Eyecool, OKYO. Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences R&D (CSRD) I01 CX002015 (Dr. Galor) and 1I01CX002633 (Dr. Galor), Biomedical Laboratory R&D (BLRD) Service I01 BX004893 (Dr. Galor), Rehabilitation R&D (RRD) I21 RX003883 (Dr. Galor). Supported by the Department of Defense Gulf War Illness Research Program (GWIRP) W81XWH-20–1-0579 (Dr. Galor) and Vision Research Program (VRP) W81XWH-20–1-0820 (Dr. Galor) and HT9425-23–1-0608 (Dr. Galor). Supported by National Eye Institute U01 EY034686 (Dr. Galor), U24EY035102 (Dr. Galor), R33EY032468 (Dr. Galor). Supported by NIH Center Core Grant P30EY014801 (institutional) and Research to Prevent Blindness Unrestricted Grant GR004596-1 (institutional). Sjögren’s Foundation 2023-PltGr-109. Darrell White—Aldeyra, Allergan/AbbVie, Bausch + Lomb, Bruder, Orasis, Nordic Pharma, Spyglass, Sun, Tarsus, Viatris/Oyster Point. Preeya Gupta—Azura, Alcon, Aldeyra, AbbVie, Bausch + Lomb, Dompe, HanAll Biopharma, Johnson & Johnson Vision, Kala, Mazado Inc, Nordic Pharma, Ocular Science, Oculis, Orasis, Sight Sciences, Science Based Health, Spyglass, Surface Ophthalmics, Tarsus, Tear Clear, Thea, Tissue Tech, Inc, Trukera, Viatris, Visionology, Vital Tears, Zeiss. James A. Stefater—EyeCool Therapeutics. Tomasz Stryjewski—EyeCool Therapeutics. Stephen Pflugfelder—Alcon, Dompe, Kala, Kowa, Unfold. Bonnie Henderson—Eyecool Therapeutics. Kaleb Abbott—Consultant: AbbVie, Alcon, Bausch + Lomb, Barti, Dompe, Harrow, Optase, Tarsus. Laura Periman – Alcon, Alderyra, Allergan/AbbVie, Amgen, Azura, Bausch + Lomb, Bruder, Dompe, Eyedetec, Kala, Lumenis, Mallinckrodt, Myze, Nordic Pharma, Novartis, Nusight Medical, Olympic Ophthalmics, Quench Method, Science Based Health, Scope, Sun, Tarrsus, Thea, Versea, Viatris, Visant. Cristos Ifantides—AbbVie, Alcon, Bausch + Lomb, EyeCool Therapeutics, JnJ, Tarsus Pharmaceuticals, Trefoil. Paul Karpecki—AbbVie, Able Therapeutics, AdOM, Alcon, Aldeyra, Aramis, Atlas, Azura, B + L, BioTissue, Blephex, Bruder, Cambium, Dompe, EyeCool Therapeutics, Harrow Health, Kala Biopharma, Lubris, Mazado, Neurolens, Nordic Pharma, Oasis Medical, Oculus, Oculis, OcuSoft, RegenerEyes, Rendia, Science Based Health, Scope, Sight Sciences, Signal 12, SilkTears, Surface, Tarsus, Thea, Tracey Tech, Viatris, Vial, Vital Tears.
: The subsequent analysis of these market data was deemed secondary research and obtained institutional review board exemption from Alpha IRB (reference number EC-01).
